
## Jasmina I Ivanova

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1059282/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Burden of illness among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: a multicenter retrospective chart review study. Annals of Hematology, 2020, 99, 743-752.	1.8	1
2	<p>Basal Insulin Initiation and Maintenance in Adults with Type 2 Diabetes Mellitus in the United States</p> . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 1023-1033.	2.4	4
3	Real-world treatment patterns among patients with advanced gastric cancer in Russia: a chart review study. Journal of Drug Assessment, 2019, 8, 150-158.	2.2	1
4	Patient and Oncologist Preferences for the Treatment of Adults with Advanced Soft Tissue Sarcoma: A Discrete Choice Experiment. Patient, 2019, 12, 393-404.	2.7	5
5	Identifying solutions to psychological insulin resistance: An international study. Journal of Diabetes and Its Complications, 2019, 33, 307-314.	2.3	23
6	Associated factors that influenced persistence with basal analog insulin therapy among people with type 2 diabetes: An exploratory analysis from a UK real-world sample. Primary Care Diabetes, 2019, 13, 106-112.	1.8	9
7	Changes in healthâ€related quality of life with longâ€term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND study. American Journal of Hematology, 2019, 94, 200-208.	4.1	22
8	Clinical burden of asynchrony in patients with asthma when using metered-dose inhalers for control. Allergy and Asthma Proceedings, 2019, 40, 21-31.	2.2	4
9	Basal insulin persistence in Brazilian participants with T2DM. Revista Da Associação Médica Brasileira, 2019, 65, 1254-1264.	0.7	1
10	Characteristics, Treatment Patterns, and Economic Outcomes of Patients Initiating Injectable Medications for Management of Type 2 Diabetes Mellitus in Japan: Results from a Retrospective Claims Database Analysis. Diabetes Therapy, 2018, 9, 1125-1141.	2.5	0
11	Insulin non-persistence among people with type 2 diabetes: how to get your patients to stay on insulin therapy. Postgraduate Medicine, 2018, 130, 394-401.	2.0	13
12	Initiation of Basal Insulin Analog Treatment for Type 2 Diabetes and Reasons Behind Patients' Treatment Persistence Behavior: Real-World Data from Germany. Experimental and Clinical Endocrinology and Diabetes, 2018, 126, 287-297.	1.2	4
13	Treatment patterns in patients with advanced gastric cancer in Taiwan. Asia-Pacific Journal of Clinical Oncology, 2017, 13, 185-194.	1.1	11
14	Basal insulin initiation use and experience among people with type 2 diabetes mellitus with different patterns of persistence: results from a multi-national survey. Current Medical Research and Opinion, 2017, 33, 1833-1842.	1.9	14
15	Correlates of basal insulin persistence among insulin-naÃ`ve people with type 2 diabetes: results from a multinational survey. Current Medical Research and Opinion, 2017, 33, 1843-1851.	1.9	18
16	Basal Insulin Persistence, Associated Factors, and Outcomes After Treatment Initiation: A Retrospective Database Study Among People with Type 2 Diabetes Mellitus in Japan. Diabetes Therapy, 2017, 8, 149-166.	2.5	13
17	Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA. Medical Oncology, 2017, 34, 193.	2.5	25
18	Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea. Cancer Research and Treatment, 2017, 49, 578-587.	3.0	19

JASMINA I IVANOVA

#	Article	IF	CITATIONS
19	Oncologist preferences in advanced soft tissue sarcoma: A discrete choice experiment Journal of Clinical Oncology, 2017, 35, 147-147.	1.6	0
20	A Retrospective Chart Review to Assess Burden of Illness Among Patients with Severe Aplastic Anemia with Insufficient Response to Immunosuppressive Therapy. Blood, 2017, 130, 678-678.	1.4	2
21	Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US. Current Medical Research and Opinion, 2016, 32, 669-680.	1.9	38
22	Patient-Reported Health-Related Quality of Life Improves over Time in Patients with Chronic Immune Thrombocytopenia Receiving Long-Term Treatment with Eltrombopag. Blood, 2016, 128, 3750-3750.	1.4	3
23	Value of Transfusion Independence in Severe Aplastic Anemia from Patients' Perspectives - a Discrete Choice Experiment. Blood, 2016, 128, 5077-5077.	1.4	Ο
24	Retrospective Analysis of Dose Titration and Serum Testosterone Level Assessments in Patients Treated With Topical Testosterone. American Journal of Men's Health, 2015, 9, 496-505.	1.6	0
25	Budget impact model of a 5-grass sublingual immunotherapy tablet for the treatment of grass pollen-induced allergic rhinitis. Journal of Medical Economics, 2015, 18, 909-918.	2.1	4
26	Glioblastoma treatment patterns, survival, and healthcare resource use in real-world clinical practice in the USA. Drugs in Context, 2015, 4, 1-12.	2.2	13
27	Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer (mCRC) treated with ziv-aflibercept (Z) in community oncology practices in the United States (US) Journal of Clinical Oncology, 2015, 33, e14554-e14554.	1.6	Ο
28	Healthcare resource use and costs of privately insured patients who switch, discontinue, or persist on anti-muscarinic therapy for overactive bladder. Journal of Medical Economics, 2014, 17, 741-750.	2.1	20
29	Duloxetine Use in Employees with Low Back Pain: Treatment Patterns and Direct and Indirect Costs. Pain Medicine, 2014, 15, 1015-1026.	1.9	2
30	Real-world treatment patterns among patients with advanced gastric cancer in South Korea Journal of Clinical Oncology, 2014, 32, 152-152.	1.6	0
31	Evaluating the Utility of Existing Patient-Reported Outcome Scales in Novel Patient Populations with Pancreatic Cancer, Lung Cancer, and Myeloproliferative Neoplasms Using Medicare Current Beneficiary Survey Data. Patient, 2013, 6, 189-200.	2.7	7
32	Costs Associated with Intravenous Cancer Therapy Administration in Patients with Metastatic Soft Tissue Sarcoma in a US Population. Sarcoma, 2013, 2013, 1-13.	1.3	3
33	The prevalence and economic impact of prescription opioid-related side effects among patients with chronic noncancer pain. Journal of Opioid Management, 2013, 9, 239-254.	O.5	22
34	Abstract 211: Association of Patient Characteristics With the Initiation of Dabigatran Versus Warfarin Among Anticoagulant Naive Patients With Non-valvular Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, .	2.2	0
35	Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma. Journal of Allergy and Clinical Immunology, 2012, 129, 1229-1235.	2.9	241
36	Duloxetine Use in Chronic Low Back Pain. Pharmacoeconomics, 2012, 30, 595-609.	3.3	7

Jasmina I Ivanova

#	Article	IF	CITATIONS
37	Physicians' Decisions to Prescribe Antidepressant Therapy in Older Patients with Depression in a US Managed Care Plan. Drugs and Aging, 2011, 28, 51-62.	2.7	10
38	Real-world practice patterns, health-care utilization, and costs in patients with low back pain: the long road to guideline-concordant care. Spine Journal, 2011, 11, 622-632.	1.3	243
39	Abstract P90: Cardiovascular and Economic Outcomes Following Initiation of Atorvastatin versus Simvastatin in an Employed Population Stratified by Cardiovascular Risk. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, .	2.2	0
40	Cost of post-traumatic stress disorder vs major depressive disorder among patients covered by medicaid or private insurance. American Journal of Managed Care, 2011, 17, e314-23.	1.1	24
41	Direct and indirect costs associated with epileptic partial onset seizures among the privately insured in the United States. Epilepsia, 2010, 51, 838-844.	5.1	50
42	Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder. Current Medical Research and Opinion, 2010, 26, 2475-2484.	1.9	105
43	Economic Burden of Epilepsy among the Privately Insured in the US. Pharmacoeconomics, 2010, 28, 675-685.	3.3	63
44	The Cost of Disability and Medically Related Absenteeism Among Employees with Multiple Sclerosis in the US. Pharmacoeconomics, 2009, 27, 681-691.	3.3	64
45	Adherence to inhaled corticosteroid use and local adverse events in persistent asthma. American Journal of Managed Care, 2008, 14, 801-9.	1.1	34